KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Deferred Tax Liability (2018 - 2023)

Vir Biotechnology's Non-Current Deferred Tax Liability history spans 6 years, with the latest figure at $3.3 million for Q1 2023.

  • For Q1 2023, Non-Current Deferred Tax Liability fell 82.36% year-over-year to $3.3 million; the TTM value through Mar 2023 reached $3.3 million, down 82.36%, while the annual FY2022 figure was $3.3 million, 82.36% down from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2023 was $3.3 million at Vir Biotechnology, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $18.4 million in Q4 2021 and bottomed at $3.3 million in Q4 2020.
  • The 5-year median for Non-Current Deferred Tax Liability is $3.3 million (2019), against an average of $7.3 million.
  • The largest annual shift saw Non-Current Deferred Tax Liability soared 466.83% in 2021 before it plummeted 82.36% in 2022.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $3.3 million in 2019, then dropped by 1.57% to $3.3 million in 2020, then skyrocketed by 466.83% to $18.4 million in 2021, then tumbled by 82.36% to $3.3 million in 2022, then changed by 0.0% to $3.3 million in 2023.
  • Per Business Quant, the three most recent readings for VIR's Non-Current Deferred Tax Liability are $3.3 million (Q1 2023), $3.3 million (Q4 2022), and $18.4 million (Q3 2022).